Pregnancy
Severe
Textbook
Fetal harm.
The risk must be weighed against the potential benefit.
Source: G&G 14e · p1392
Drug reference
trametinib
MEK inhibitor, kinase inhibitor · antineoplastic, targeted therapy
MEK inhibitor, kinase inhibitorantineoplastic, targeted therapy
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
1 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactions
- PregnancySevereTextbookG&G 14e · p1392
Mechanism
MEK inhibitor.
Indications
anaplastic carcinomas containing BRAF V600E (FDA-approved in combination with dabrafenib)redifferentiation therapy (with or without BRAF inhibition) to induce radioiodine uptake in non–iodine-avid thyroid cancersmutant BRAF V600E/K melanoma (monotherapy, though combination with dabrafenib is preferred)mutant V600E/K metastatic melanoma (in combination with dabrafenib)mutant V600E metastatic NSCLC (in combination with dabrafenib)metastatic anaplastic thyroid cancer (in combination with dabrafenib)combination with BRAF inhibitors for melanomas that harbor a mutation at position 600 in BRAF
Pharmacokinetics
Peak effect
1.5 h
Half-life
4 to 5 days
Bioavailability
72% (oral)
Metabolism
not a substrate of CYP enzymes
Side effects
Common
cutaneous rashacneiform dermatitisdiarrheafatiguenausealymphedemaheadachepyrexiaarthralgias
Serious
- grade 3 to 4 skin toxicity (6% of patients)
- cardiomyopathy
- hypertension
- hemorrhage
- interstitial lung disease
- ocular toxic effects
- cardiac toxicities
- ocular toxicities
Pregnancy & lactation
Pregnancy
D
Drug interactions
11 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other MEK inhibitor, kinase inhibitor drugs
Ask House about trametinib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team